Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Vaccine. 2011 Feb 1;29(6):1194-200. doi: 10.1016/j.vaccine.2010.12.002. Epub 2010 Dec 16.
The newly established HLA-A2.1 transgenic rabbit model has proven useful for testing the immunogenicity of well known and computer-predicted A2-restricted epitopes. In the current study we compared the protective immunity induced to a preferred HPV16 E7 A2-restricted epitope that has been relocated to positions within the CRPV E7 gene and the CRPV L2 gene. Epitope expression from both the E7 protein and the L2 protein resulted in increased protection against viral DNA challenge of the HLA-A2.1 transgenic rabbits as compared to control-vaccinated rabbit groups. These data indicate that proteins expressed at both early and late time points during a natural papillomavirus infection can be targeted by epitope-specific immunity and indicate this immunity is increased to early rather than late expressed proteins of papillomaviruses. This study also highlights the broad utility of the HLAA2.1 transgenic rabbit model for testing numerous immunological factors involved in vaccine generated protective immunity.
新建立的 HLA-A2.1 转基因兔模型已被证明可用于测试已知和计算机预测的 A2 限制性表位的免疫原性。在本研究中,我们比较了对 HPV16 E7 A2 限制性表位的保护性免疫,该表位已被重新定位到 CRPV E7 基因和 CRPV L2 基因内的位置。与对照疫苗接种兔组相比,来自 E7 蛋白和 L2 蛋白的表位表达导致 HLA-A2.1 转基因兔对病毒 DNA 挑战的保护增加。这些数据表明,在天然乳头瘤病毒感染过程中早期和晚期表达的蛋白都可以被表位特异性免疫靶向,并表明这种免疫对乳头瘤病毒早期而不是晚期表达的蛋白增加。这项研究还强调了 HLA-A2.1 转基因兔模型在测试与疫苗产生的保护性免疫有关的众多免疫因素方面的广泛应用。